Chronic cough, defined as a cough persisting for more than eight weeks, is a common yet challenging condition encountered in primary care. It significantly impacts the quality of life and necessitates a comprehensive understanding for effective management.
The pathophysiology of chronic cough is multifactorial, often associated with conditions such as gastroesophageal reflux disease (GERD), asthma, and upper airway cough syndrome (UACS). However, in some cases, the cause remains unidentifiable, leading to the term 'idiopathic chronic cough'.
A thorough history and physical examination form the cornerstone of diagnosis. Investigations such as chest X-ray, spirometry, and bronchoscopy may be warranted based on clinical suspicion. Empirical treatment trials for common causes like GERD and UACS may also aid in identifying the underlying etiology.
Treatment is primarily aimed at addressing the underlying cause. For instance, proton pump inhibitors for GERD, inhaled corticosteroids for asthma, and antihistamines for UACS. Moreover, cough suppressants and behavioural therapy play a crucial role in managing idiopathic chronic cough.
Recent advancements have introduced novel therapies targeting neuronal pathways involved in cough reflex. P2X3 antagonists, such as gefapixant, have shown promising results in reducing cough frequency, thus offering potential new avenues for treatment.
Chronic cough is a complex condition requiring a comprehensive approach for diagnosis and management. Understanding the underlying mechanisms, adopting a systematic diagnostic approach, and being aware of the latest advancements in treatment strategies are crucial for healthcare professionals in providing optimal patient care. Ongoing research into the pathophysiology of chronic cough and the development of novel treatments is likely to further improve patient outcomes in the future.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation